Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 1, 2011, Pages 127-137

  Freedman, N D ^a   Curto, T M ^b   Morishima, C ^c   Seeff, L B ^d   Goodman, Z D ^e   Wright, E C ^d   Sinha, R ^a   Everhart, J E ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; COLLAGEN; PEGINTERFERON ALPHA2A; RIBAVIRIN; SILYMARIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; DRUG USE; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER LEVEL; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT DURATION;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; PROTECTIVE AGENTS; SILYMARIN; TREATMENT OUTCOME;

EID: 78650028517     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04503.x     Document Type: Article

References (34)

1. Lavanchy D,. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl. 1): 74-81.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
4. Stickel F, Schuppan D,. Herbal medicine in the treatment of liver diseases. Dig Liver Dis 2007; 39: 293-304.
5. Verma S, Thuluvath PJ,. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol 2007; 5: 408-16.
6. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C,. Milk thistle for alcoholic and/or hepatitis B or C liver diseases-a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100: 2583-91.
7. Seeff LB, Curto TM, Szabo G, et al. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial. Hepatology 2008; 47: 605-12.
8. Shibano M, Lin AS, Itokawa H, Lee KH,. Separation and characterization of active flavonolignans of Silybum marianum by liquid chromatography connected with hybrid ion-trap and time-of-flight mass spectrometry (LC-MS/IT-TOF). J Nat Prod 2007; 70: 1424-8.
9. Morishima C, Shuhart MC, Wang CC, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 2010; 138: 671-81.
10. Trappoliere M, Caligiuri A, Schmid M, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 2009; 50: 1102-11.
11. Polyak SJ, Morishima C, Shuhart MC, et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 2007; 132: 1925-36.
12. Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010; 138: 1112-22.
13. Bonifaz V, Shan Y, Lambrecht RW, et al. Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int 2009; 29: 366-73.
14. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-7.
15. Pietrangelo A, Borella F, Casalgrandi G, et al. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995; 109: 1941-9.
16. Boigk G, Stroedter L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997; 26: 643-9.
17. Dehmlow C, Erhard J, De Groot H,. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23: 749-54.
18. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-41.
19. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
20. Goodman ZD, Becker RL Jr, Pockros PJ, Afdhal NH,. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 2007; 45: 886-94.
21. Goodman ZD, Stoddard AM, Bonkovsky HL, et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009; 50: 1738-49.
22. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R,. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
23. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-48.
24. Cox DR,. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972; 34: 187.
25. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
26. Ghany MG, Lok AS, Everhart JE, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010; 138: 136-46.
27. Mayer KE, Myers RP, Lee SS,. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 2005; 12: 559-67.
28. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105-13.
29. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998; 28: 615-21.
30. Strickland GT, Tanamly MD, Tadros F, et al. Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C. Dig Liver Dis 2005; 37: 542-3.
31. Tanamly MD, Tadros F, Labeeb S, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis 2004; 36: 752-9.
32. Cho YK, Yun JW, Park JH, et al. Deleterious effects of silymarin on the expression of genes controlling endothelial nitric oxide synthase activity in carbon tetrachloride-treated rat livers. Life Sci 2009; 85: 281-90.
33. Gordon A, Hobbs DA, Bowden DS, et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 275-80.
34. Schrieber SJ, Wen Z, Vourvahis M, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos 2008; 36: 1909-16.